Strategic responses of pharmaceutical companies and healthcare organisations to maintain competitive advantage in the cataract market

Purpose: Recent studies highlighted the increase of competiveness and fluctuation in pharmaceutical market share, the industry facing tremendous pressure. Hence the sector has the necessity to embrace the goal of delivering their products and services with value. Specifically, diabetes care in the pharmaceutical industry has been an important agenda for providing high quality services and products to the customers in past few decades. Therefore, the present paper critically views the impact of value discipline dimensions on organizational performance and competitive advantage of diabetes care in both developed and developing countries.Design/ methodology/ Approach: This research involves in secondary data collection due to achieving the objectives framed. Moreover, it perceives the association between the variables is not possible, conducting interviews with respondents in both developed and developing countries are also difficultFindings: The finding shows that there is animpact of value discipline dimensions on organizational performance and competitive advantage of diabetes care in both developed and developing countries via secondary data collection method. Research Limitations/ Implications: This study is limited to secondary research and all the findings inferred are from the information available from secondary sources.Practical implications: The impact of value discipline dimensionson organizational performance and competitive advantage of diabetes care is effective in the context of both developed and developing countries.Originality/ Value: Understanding the value discipline dimensions impact on organizational performance and competitive advantage of diabetes care is anew one. Hence this paper proposes this concept in both developed and developing countries perspective.

Download Full-text

TWO-SIDED EFFECTS OF EMBEDDEDNESS IN ALLIANCE PORTFOLIOS

International Journal of Innovation Management ◽

10.1142/s1363919615500413 ◽

2015 ◽

Vol 19 (04) ◽

pp. 1550041 ◽

Cited By ~ 1

Author(s):

MARCO JINHWAN KIM ◽

GUNNO PARK ◽

JINA KANG

Keyword(s):

Competitive Advantage ◽

Empirical Test ◽

Innovation Performance ◽

Pharmaceutical Companies ◽

Technology Alliances ◽

Alliance Portfolios

Alliance portfolios are an important source of competitive advantage for firms. Diverse resources of partners contribute to enhancing firms' performance, but relationships among the firms' partners also influence the performance. This paper, employing an embeddedness lens, aims to examine how these relationships influence the firms' innovation performance. We confirm two-sided effects of embeddedness within alliance portfolios. While the focal firms increase the size of their portfolios, dense relationships among their partners increase the performance and competitive relationships weaken the performance. For the empirical test, we collected data on 1863 technology alliances between US biotechnology and multinational pharmaceutical companies. This study highlights how firms have to consider relationships among their partners when configuring their alliance portfolios to maximise innovation performance.

Download Full-text

Managerial competencies and competitive advantage in pharmaceutical blockbusters

International Journal of Business, Management & Economics Research ◽

10.47747/ijbme.v2i1.223 ◽

2021 ◽

Vol 2 (1) ◽

pp. 53-79

Author(s):

Abiodun Taiwo Olafenwa ◽

Ahmed Adeniyi Ojikutu ◽

Oladapo Alani Owoeye

Keyword(s):

Competitive Advantage ◽

Support Groups ◽

Quantitative Research ◽

Primary Data ◽

Pharmaceutical Companies ◽

Organisational Performance ◽

Competitive Strategies ◽

Managerial Competencies ◽

Strong Positive Relationship ◽

The Face

The study empirically tested the relationship between managerial competencies and competitive advantage in pharmaceutical blockbusters. According to the literature, blockbuster models and competitive strategies are significant determinants in organisational performance in the pharmaceutical industry context. However, the focus of this study is to determine whether efforts to combine managerial competence and the blockbuster model will reorient pharmaceutical companies to better competitive advantage by creating blockbuster drugs for the companies. This competitive advantage will position pharmaceutical companies in the face of increasing labour turnover, daunting economic challenges and perceived customer benefits that characterise this industry. A quantitative research design was adopted for this study, and primary data were obtained through a structured questionnaire administered to 22 managers of two major pharmaceutical firms in Lagos, Nigeria. The data obtained revealed a strong positive relationship between managerial competencies, blockbuster models and competitive advantage and three out of four hypotheses were accepted. The hypotheses were tested through Pearson’s product-moment correlation and regression product of determination. Descriptive statistical tools, ANOVA and multiple linear regressions were used to assess perceptions of managerial competencies and blockbuster models on SPSS (version 23.0). Cronbach’s alpha was extracted as a reliability coefficient for the data analysis (α = 0.851). Several implications for management and policy are also discussed in light of the findings of this study. It was concluded that a deep knowledge of managerial competencies and blockbuster models are highly needed in the selected pharmaceutical companies to gain business expansion, maintain low average costs and achieve significant market share while improving on their level of service delivery and capacity to support groups or teams through training, coaching and sharing specialist knowledge. This study recommends developing strategies and deploying blockbuster models across all industries for a distinctive advantage of ineffective organisational performance and greater productivity.

Download Full-text

Critical Success Factors for Competitive Advantage in Iranian Pharmaceutical Companies: A Comprehensive MCDM Approach

Mathematical Problems in Engineering ◽

10.1155/2021/8846808 ◽

2021 ◽

Vol 2021 ◽

pp. 1-17

Author(s):

Amir Karbassi Yazdi ◽

Farhan Muhammad Muneeb ◽

Peter Fernandes Wanke ◽

Otavio Figueiredo ◽

Irum Mushtaq

Keyword(s):

Competitive Advantage ◽

Performance Indicators ◽

Critical Success Factors ◽

Success Factors ◽

Rapid Development ◽

Multiple Criteria Decision Making ◽

Superior Performance ◽

Pharmaceutical Companies ◽

Manufacturing Strategy ◽

Critical Success

The unprecedented COVID-19 outbreak strengthened the critical manifestation of the rapid development vs. survival for pharmaceutical companies, deploying strategic conduct worldwide. This study therefore explores the endogenous relationship among pharmaceutical companies’ manufacturing strategy and their performance indicators within the ambit of creating a long-lasting competitive advantage in turbulent times. Very often, it is not possible to launch a cause-effect relationship between performance and their drivers. To achieve this end, multiple-criteria decision-making (MCDM) techniques are employed in a hybrid fashion in this study. The notion has simultaneously ranked critical success factors (CSFs) in the manufacturing strategy and performance indicators in the limelight of managerial perceptions, while controlling the inherent bias concerning the causality direction in the ambit of these two entrenched concepts. A case study on the Iranian pharmaceutical companies is piloted to demonstrate this hybrid-fashion multifarious approach. Overall, the results revealed the most pertinent CSFs that reached superior-performance echelons in the Islamic Republic of Iran.

Download Full-text

Sustainable Supply Chain Responsiveness Impact of Strategies Competitive Advantage in Jordanian Pharmaceutical Companies

10.7176/ejbm/12-26-02 ◽

2020 ◽

Keyword(s):

Supply Chain ◽

Competitive Advantage ◽

Pharmaceutical Companies ◽

Sustainable Supply Chain

Download Full-text

Innovation through M&A in the biopharmaceutical sector

Strategic Direction ◽

10.1108/sd-03-2016-0037 ◽

2016 ◽

Vol 32 (6) ◽

pp. 27-29 ◽

Cited By ~ 1

Author(s):

Arsia Amir-Aslani ◽

Mark Anthony Chanel

Keyword(s):

Competitive Advantage ◽

Design Methodology ◽

Reading Time ◽

Core Competency ◽

Pharmaceutical Companies ◽

Content Type ◽

The Core ◽

Sustainable Advantage ◽

Pertinent Information ◽

Practical Implications

Purpose This paper aims to review the latest management developments across the globe and pinpoint practical implications from cutting-edge research and case studies. Design/methodology/approach This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context. Findings Acquiring innovation will continue to be a necessity for pharmaceutical companies and to enjoy a sustainable advantage, they have the obligation to look for competitive advantage through coordination between both upstream and downstream capacities. A strict focus on the core competency of the enterprise is fast becoming obsolete. Practical implications The paper provides strategic insights and practical thinking that have influenced some of the world’s leading organizations. Originality/value The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent information and presenting it in a condensed and easy-to-digest format.

Download Full-text